CN1253554A - 杂环化合物及其抑制β-淀粉样肽的用途 - Google Patents

杂环化合物及其抑制β-淀粉样肽的用途 Download PDF

Info

Publication number
CN1253554A
CN1253554A CN98802875A CN98802875A CN1253554A CN 1253554 A CN1253554 A CN 1253554A CN 98802875 A CN98802875 A CN 98802875A CN 98802875 A CN98802875 A CN 98802875A CN 1253554 A CN1253554 A CN 1253554A
Authority
CN
China
Prior art keywords
phenyl
base
alkyl
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98802875A
Other languages
English (en)
Chinese (zh)
Inventor
E·D·托尔瑟特
W·J·波特
J·S·尼森
L·H·拉蒂默
J·E·奥迪尔
J·J·德罗斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Eli Lilly and Co
Original Assignee
Elan Pharmaceuticals LLC
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC, Eli Lilly and Co filed Critical Elan Pharmaceuticals LLC
Publication of CN1253554A publication Critical patent/CN1253554A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN98802875A 1997-02-28 1998-02-27 杂环化合物及其抑制β-淀粉样肽的用途 Pending CN1253554A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80826397A 1997-02-28 1997-02-28
US08/808,263 1997-02-28

Publications (1)

Publication Number Publication Date
CN1253554A true CN1253554A (zh) 2000-05-17

Family

ID=25198310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98802875A Pending CN1253554A (zh) 1997-02-28 1998-02-27 杂环化合物及其抑制β-淀粉样肽的用途

Country Status (22)

Country Link
EP (1) EP0968198A1 (hu)
JP (1) JP2001513107A (hu)
KR (1) KR20000075767A (hu)
CN (1) CN1253554A (hu)
AR (1) AR011164A1 (hu)
AU (1) AU6662298A (hu)
BR (1) BR9807876A (hu)
CA (1) CA2278674A1 (hu)
CO (1) CO4920244A1 (hu)
EA (1) EA199900778A1 (hu)
HR (1) HRP980093A2 (hu)
HU (1) HUP0001293A3 (hu)
ID (1) ID22873A (hu)
IL (1) IL130851A0 (hu)
NO (1) NO994016L (hu)
NZ (1) NZ336613A (hu)
PE (1) PE59399A1 (hu)
PL (1) PL335424A1 (hu)
TR (1) TR199902071T2 (hu)
WO (1) WO1998038177A1 (hu)
YU (1) YU7998A (hu)
ZA (1) ZA981627B (hu)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103435549A (zh) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法
CN105646208A (zh) * 2016-02-24 2016-06-08 潍坊晶润化工有限公司 丙酮酸甲酯的制备方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1999032453A1 (en) * 1997-12-22 1999-07-01 Elan Pharmaceuticals, Inc. POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911803D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
AU6420700A (en) * 1999-08-05 2001-03-05 Prescient Neuropharma Inc. Novel 1,4-benzodiazepine compounds and derivatives thereof
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
EP1268450A1 (en) 2000-06-01 2003-01-02 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a-beta protein production
DE10029077A1 (de) * 2000-06-13 2001-12-20 Bayer Ag Thiazolylsubstituierte Heterocyclen
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
FR2840899B1 (fr) * 2002-06-12 2005-02-25 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
WO2003106689A1 (ja) 2002-06-05 2003-12-24 鐘淵化学工業株式会社 光学活性α−メチルシステイン誘導体の製造方法
WO2006034003A2 (en) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
JP2010505870A (ja) 2006-10-03 2010-02-25 アレイ バイオファーマ、インコーポレイテッド 有糸分裂キネシン阻害剤としてのオキサジアゾール誘導体およびチアジアゾール誘導体、ならびにそれらの使用方法
WO2010006792A1 (de) * 2008-07-16 2010-01-21 Bitop Ag Synthese von zyklischen amidinen
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506923A (ja) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ,インコーポレイテッド 新しいカテプシンならびにその阻害のための方法および組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103435549A (zh) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法
CN105646208A (zh) * 2016-02-24 2016-06-08 潍坊晶润化工有限公司 丙酮酸甲酯的制备方法

Also Published As

Publication number Publication date
HUP0001293A3 (en) 2000-09-28
EA199900778A1 (ru) 2000-04-24
AR011164A1 (es) 2000-08-02
HUP0001293A1 (hu) 2000-08-28
CA2278674A1 (en) 1998-09-03
ID22873A (id) 1999-12-16
TR199902071T2 (xx) 2000-01-21
NO994016L (no) 1999-10-18
BR9807876A (pt) 2000-02-29
AU6662298A (en) 1998-09-18
CO4920244A1 (es) 2000-05-29
HRP980093A2 (en) 1998-12-31
IL130851A0 (en) 2001-01-28
ZA981627B (en) 1999-10-05
PL335424A1 (en) 2000-04-25
YU7998A (sh) 2002-06-19
NO994016D0 (no) 1999-08-19
KR20000075767A (ko) 2000-12-26
WO1998038177A1 (en) 1998-09-03
PE59399A1 (es) 1999-06-21
NZ336613A (en) 2001-10-26
JP2001513107A (ja) 2001-08-28
EP0968198A1 (en) 2000-01-05

Similar Documents

Publication Publication Date Title
CN1253554A (zh) 杂环化合物及其抑制β-淀粉样肽的用途
CN1171878C (zh) 化合物、其用途以及含有所述化合物的药物组合物
CN1207288C (zh) 逆病毒蛋白酶抑制化合物
CN1033584C (zh) 促进生长激素释放的新的苯并稠合内酰胺的制法
CN1253441C (zh) 蛋白酶抑制剂
CN1244561C (zh) 可用作生长激素促分泌素的四氢异喹啉类似物
CN1225471C (zh) 具有生长激素释放特性的化合物
CN1192035C (zh) 白介素-1β转化酶抑制剂
CN1034733C (zh) 促进生长激素释放的螺哌啶类化合物和同系物
CN1174504A (zh) 促进生长激素释放的哌啶、吡咯烷和六氢-1h-吖庚因
CN1238760A (zh) N-(芳基/杂芳基/烷基乙酰基)氨基酸酰胺类,含有这类化合物的药物组合物,及用这类化合物抑制β-淀粉样肽释放和或合成的方法
CN1237960A (zh) N(-芳基/杂芳基乙酰基)氨基酸酯、包括这些酯的药用组合物以及用这些化合物抑制β淀粉样肽释放和/或合成的方法
CN1882591A (zh) 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶
CN1237978A (zh) N-(芳基/杂芳基)氨基酸衍生物、包括这些衍生物的药用组合物以及用这些化合物抑制β-淀粉样肽释放和或其合成的方法
CN1386118A (zh) 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
CN1238779A (zh) 抑制β-淀粉样肽释放和/或其合成的方法和化合物
CN1230110A (zh) 细胞粘连抑制剂
CN1143647A (zh) 促进生长激素释放的二肽
CN1768041A (zh) 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
CN1974596A (zh) 丙型肝炎病毒抑制剂
CN1085546A (zh) 胺二醇蛋白酶抑制剂
CN1233237A (zh) 杂芳基琥珀酰胺类化合物及其作为金属蛋白酶抑制剂的应用
CN1751047A (zh) 可用于治疗的三唑化合物
CN1436175A (zh) 作为Aβ-蛋白生产抑制剂的环状内酰胺
CN1305993A (zh) 用作氧化氮合成酶抑制剂的环状脒基制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication